Brokers Set Expectations for INKT Q1 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of MiNK Therapeutics in a note issued to investors on Friday, November 7th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.90) for the quarter. HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q2 2026 earnings at ($1.04) EPS, Q3 2026 earnings at ($0.93) EPS and Q4 2026 earnings at ($1.03) EPS.

Several other research analysts also recently weighed in on the company. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 20th. Wall Street Zen lowered shares of MiNK Therapeutics to a “strong sell” rating in a research report on Saturday, August 23rd. B. Riley upgraded shares of MiNK Therapeutics to a “strong-buy” rating in a research report on Friday, July 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

MiNK Therapeutics Stock Up 4.1%

Shares of INKT stock opened at $13.77 on Monday. The stock’s 50-day moving average price is $14.39 and its 200 day moving average price is $12.72. The stock has a market capitalization of $62.28 million, a PE ratio of -4.78 and a beta of 0.33. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Thursday, August 14th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51).

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.